EDIT editasmedicine.com: Operatsion rentabellik

Ommaviy kompaniya Editas Medicine, Inc. (EDIT) logotipi

Editas Medicine, Inc. (EDIT) CRISPR patentlarining monetizatsiyasi va reni-cel terapiyasiga tikmoqda. Operatsion marja tahlili daromadlilik dinamikasini namoyish etadi, bunda -167.00 qiymati ushbu metrikani aks ettiradi. Kompaniya qon va ko'rish qobiliyati buzilishlari uchun davolash usullarini ishlab chiqish orqali risklarni minimallashtirmoqda. Faol R&D loyihalari hozirda Cas12a texnologiyasining qo'llanilishiga oid inqilobiy ma'lumotlarni tayyorlashga qaratilgan.

EDIT: Editas Medicine Inc Sotuvning operatsion rentabelligi 04.07.2022 - 20.11.2026

EDIT (editasmedicine.com): tahliliy kesimlar va indikatorlar boʻyicha maʼlumotlar

- aksiya narxi va baholash bo'yicha konsensus prognoz:
- kompaniya aksiyalari kapitallashuvi ma'lumotlari:
Kompaniyaning umumiy tahlili:Editas Corp, EDIT
Editas Medicine, Inc. tayyor mahsulotlari

Konservativ kapital biznes barqarorligini baholash uchun operatsion samaradorlik bo'yicha mutlaq shaffoflikni talab qiladi. Ushbu ko'rsatkich soliqlar va foiz to'lovlarigacha bo'lgan barcha ishlab chiqarish xarajatlari qoplanilgandan keyin qolgan daromad qismini belgilaydi. Editas Medicine, Inc. (EDIT) uchun ushbu metrika noyob CRISPR texnologiyasiga bo'lgan elastik bo'lmagan talabni monetizatsiya qilish qobiliyatini ifodalaydi. Genlarni tahrirlashdagi yuqori narx belgilash imkoniyati daromadlilik o'sishiga aylanishi kerak. Operatsion marjaning o'zgarishlar tarixi ushbu jarayonni aniq namoyish etadi.

Raqobatdosh kompaniyalar tahlili

Sotuvning operatsion marjasi TEM|QGEN - Operatsion foyda bo'yicha marjinallik|Operatsion marja IONS|RGEN - Sotuvning operatsion rentabelligi|Operatsion rentabellik Avidity RNA|Operatsion marja CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operatsion marja|Ultragenyx Pharma (RARE) - Sotuvning operatsion marjasi|beamtx.com (BEAM) - Operatsion rentabellik|SRPT: Operatsion foyda koeffitsiyenti|Sotuvning operatsion marjasi TWST|TXG - Operatsion foyda bo'yicha marjinallik|Operatsion marja NTLA|Operatsion faoliyat rentabelligi Stoke Therapeutics|Operatsion rentabellik BioLife Solutions BLFS|Wave Life Sciences (WVE) - Sotuvning operatsion rentabelligi|Maze Therapeutics, Inc. - Operatsion marja|Operatsion faoliyat rentabelligi Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Operatsion rentabellik|TSHA: Operatsion foyda koeffitsiyenti|Operatsion rentabellik uniQure Pharma|MGTX - Operatsion foyda bo'yicha marjinallik|Operatsion marja RGNX|Operatsion rentabellik SLDB (Solid Biosciences)|Ocugen Corp - Sotuvning operatsion marjasi|PACB: Operatsion foyda bo'yicha sotuv rentabelligi|benitec.com - Operatsion marja|DSGN - Operatsion marja|RCKT: Operatsion marja|FDMT (4D Molecular Therapeutics Inc) - Operatsion rentabellik|Sotuvning operatsion marjasi LXEO|Operatsion rentabellik KRRO|Operatsion marja SLN|ProQR Therapeutics - Operatsion foyda bo'yicha sotuv rentabelligi|Operatsion marja CDXS (Codexis, Inc.)|SGMO: Operatsion foyda bo'yicha sotuv rentabelligi|Nautilus Biotechnology - Operatsion marja|Operatsion foyda normasi MGX (Metagenomi, Inc)|DTIL: Operatsion marja|GBIO: Operatsion foyda koeffitsiyenti|Operatsion rentabellik Boundless Bio Inc.|Sotuvning operatsion marjasi Exicure (XCUR)|Operatsion marja IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operatsion foyda normasi|Mustang Bio, Inc. - Sotuvning operatsion marjasi|RNAZ - Sotuvning operatsion marjasi|BNGO: Sotuvning operatsion marjasi|APDN (Applied DNA Sciences Inc) - Operatsion foyda bo'yicha sotuv rentabelligi|BLUE (Bluebird Bio) - Sotuvning operatsion marjasi|ImmunoPrecise Antibodies Ltd - Operatsion foyda normasi|OMGA (Omega Therapeutics Inc) - Operatsion marja|Operatsion rentabellik OMIC|Operatsion rentabellik Regulus Therapeutics Inc. (RGLS)|Sotuvning operatsion marjasi Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Sotuvning operatsion marjasi|Operatsion foyda normasi TCON|UBX - Operatsion rentabellik